CompletedPhase 1

Study to Assess the Safety and Pharmacokinetics of ATL-001 (Ciclopirox Olamine) in Healthy Volunteers

United States42 participantsStarted 2023-03-31

Plain-language summary

The goal of this clinical trial is to assess the safety, tolerability and pharmacokinetics of ATL-001 (ciclopirox olamine) in healthy volunteers

Who can participate

Age range18 Years – 65 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Healthy male or female subjects 18 to 65 years of age, inclusive
✓. Body mass index (BMI) within the range of 18.0 to 33.0 kg/m2, inclusive, and a minimum weight of at least 50.0 and maximum weight of 100.0 kg at Screening
✓. Estimated Glomerular Filtration Rate (eGFR) \> 90 mL/min/1.73 m2 at Screening
✓. Female subjects of childbearing potential must be using and willing to continue using two medically acceptable contraceptive precautions from Screening and for at least 1 month after the last study drug administration. Medically acceptable forms of contraception include sexual abstinence \[periodic abstinence (e.g., calendar, ovulation, symptothermal and post-ovulation methods) are not acceptable\], combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal or transdermal), intrauterine devices (IUD), intrauterine hormone-releasing systems, and bilateral tubal ligation for subjects
✓. Female subjects of non-childbearing potential must be amenorrhoeic for at least 2 years or had a hysterectomy and/or bilateral oophorectomy/salpingo-oophorectomy (as determined by subject medical history)
✓. Male subjects of reproductive potential with a partner(s) of childbearing potential must be using and willing to continue using two medically acceptable contraceptive precautions from Screening and for at least 1 month after the last study drug administration. Medically acceptable forms of contraception include abstinence, vasectomy, or male condom for subjects
✓. Female subjects must have a negative pregnancy test
✓. Must understand and provide written informed consent prior to the initiation of any protocol-specific procedures

Exclusion criteria

✕. Current drug or alcohol dependence (excluding caffeine), based on self-report, including subjects who have been in a drug rehabilitation program
✕. Current smoker or a history of using tobacco products within 3 months prior to Screening
✕. Clinically significant abnormalities on physical examination, medical history, 12-lead ECG (i.e., QTc \> 440 ms for male subjects and \> 450 ms for female subjects), vital signs, or laboratory values, as judged by the investigator or designee
✕. History or presence of any clinically significant illness (e.g., cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, musculoskeletal, or psychiatric) or any other condition, which in the opinion of the investigator would jeopardize the safety of the subject or the validity of the study results
✕. Use of a non-prescription drug within 14 days prior to the first drug administration. Subjects who have taken over-the-counter medication may still be entered into the study, if in the opinion of the investigator or designee, the medication received will not interfere with the study procedures or data integrity or compromise the safety of the subject
✕. Use of any prescription medications, recreational drugs, or natural health products (except vitamin or mineral supplements, acceptable forms of birth control, and hormone replacement) within 14 days prior to first drug administration or throughout the study, unless in the opinion of the investigator or designee, the product will not interfere with the study procedures or data integrity or compromise the safety of the subject
✕. Use of any medication that interfere with the glucuronidation metabolic pathway within 14 days prior to first drug administration
✕. Positive urine drug screen

What they're measuring

Incidence of adverse events (AEs)

Timeframe: 3.5 months, with up to 66 days per participant

Trial details

NCT IDNCT05647343

SponsorAtlas Molecular Pharma

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2024-04-08

View on ClinicalTrials.gov More Adverse Effect of Drugs and Medicaments in Therapeutic Use trials